In addition, the lncRNA APCDC1L-AS can induce resistance to erktinib (EGFR-tyrosine kinase inhibitor) in lung adenocarcinoma by inhibiting autophagic degradation of epithelial growth factor receptor (EGFR) (52, 53). Here, EGFR is linked to lung adenocarcinoma.